Abstract
Introduction: C-19 presents a varied clinical picture, from asymptomatic cases, to pneumonia and multiple organ failure associated with severe inflammation and death. Impaired anti-inflammatory responses and pre-existing lung disease may increase risk in AATD1. We sought to estimate this risk.
Methods: Participating centres2 identified AATD patients (PiZZ, PiSZ or rare severe variants) with C-19 via clinical contact and patient-group awareness. Anonymised data collected by patient-reporting were entered into a central database and analysed using SPSS.
Results: 57 patients (37, male) from 8 countries were identified. Genotype distribution was PiZZ 39, PiSZ 8, other severe variants 10. 10 patients were receiving regular IV augmentation therapy. Mean (sd) age was 51 (11.2), AAT level was 0.3 (0.2) g/L, baseline FEV1 %pred 61 (28) BMI 27 (5). 40 patients had emphysema, 8 had liver disease, 11 hypertension and 1 diabetes. 52 patients had positive PCR and 5 patients, typical C-19 symptoms (PCR negative). 21 required hospital admission, 15 had high flow oxygen therapy, 4 NIV/CPAP and 3 required ITU admission. Length of hospital / ITU admission was 11 (3) / 6 (4) days. 3 (5%) patients died. Post-COVID FEV1 %pred was 60 (29).
Conclusions: Severe AATD does not represent the level of risk predicted from perceived pathogenetic mechanisms. Selection bias may have influenced our data. Further confirmatory data are required but these preliminary findings may provide some guidance.1Yang C. et al. Lancet Respir Med. 2021 Jan https://doi.org/10.1016/S2213-2600(21)00018-72.2 Miravitlles M. et al. Eur Respir J. 2019 Feb 14;53(2):1900138.
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA2365.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021